The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era

Zheng Li; Yue Hu; Ming Zeng; Qinyong Hu; Fei Ye; Ruifeng Liu; Hongyi Cai; Qiang Li; Xiaohu Wang

doi:10.3389/fonc.2022.976143

The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era

Front Oncol. 2022 Sep 14:12:976143. doi: 10.3389/fonc.2022.976143. eCollection 2022.

Authors

Zheng Li^{1

2}, Yue Hu³, Ming Zeng⁴, Qinyong Hu⁵, Fei Ye¹, Ruifeng Liu^{1

2}, Hongyi Cai⁶, Qiang Li^{1

2}, Xiaohu Wang^{1

2}

Affiliations

¹ Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
² Lanzhou Heavy Ion Hospital, Lanzhou, China.
³ Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
⁴ Department of Radiation Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, United States.
⁵ Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
⁶ Department of Radiotherapy, Gansu Provincial Hospital, Lanzhou, China.

Abstract

The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by the COVID-19 pandemic, which is helpful for the optimal risk-benefit profile.

Keywords: COVID-19; SARS-CoV-2; artificial intelligence; liver neoplasms; medical resource; radiotherapy; telemedicine.

Publication types

Review